Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
ADMA BIOLOGICS, INC.
Bear Case (25th pct.)
-33.4% vs price
Base Case (Median)
-4.9% vs price
Bull Case (75th pct.)
4.2% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $9.80 | 0.8% | High (40%) |
| PE Comparable | $15.72 | 61.6% | Medium (25%) |
| Graham Number | $5.74 | -41.0% | Medium (40%) |
| EV/EBITDA | $8.70 | -10.5% | Medium (20%) |
| EV/FCF | $10.24 | 5.3% | Medium (20%) |
| Earnings Power Value | $4.71 | -51.5% | Medium (50%) |
Based on 6 out of 7 methods, ADMA appears fairly valued at the current price of $9.72. The base case fair value of $9.25 implies 4.9% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.